Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aveeno Eczema Therapy Nighttime Moisturizing Balm is an over-the-counter topical skin protectant developed by Johnson & Johnson Consumer Inc. for the management of mild to moderate atopic dermatitis (eczema). The formulation contains 1% colloidal oatmeal as its active ingredient, which works by forming a physical barrier on the skin surface, increasing hydration of the stratum corneum, and reducing transepidermal water loss. Clinical studies have demonstrated that the product also positively influences the skin microbiome by supporting the growth of beneficial commensal bacteria and helps restore a healthy skin pH. It is designed for use in both infants and adults to provide long-lasting relief from itching and irritation associated with eczema.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aveeno Eczema Therapy Nighttime Moisturizing Balm.